Brief: Oasmia Pharmaceutical Signs Phase 1B Trial Agreement With SAKK
08/06/2020 06:04
June 8 (Reuters) - Oasmia Pharmaceutical AB OASM.ST :
* OASMIA PHARMACEUTICAL AB SIGNS PHASE 1B TRIAL AGREEMENT
WITH
SAKK, THE SWISS GROUP FOR CLINICAL CANCER RESEARCH FOR
EVALUATION OF DOCETAXEL MICELLAR
* PARTNERED WITH SWISS GROUP FOR CLINICAL CANCER RESEARCH
(SAKK)
TO CONDUCT FIRST CLINICAL TRIAL OF OASMIA'S DOCETAXEL MICELLAR
COMPOUND IN ADVANCED PROSTATE CANCER
Source text for Eikon: ID:nNDL6Wd3RV
Further company coverage: OASM.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))